Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROMAX trial of pre-hospital bivalirudin versus heparin-based standard care in STEMI
NL-OMON38053Phase 3Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Nov 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bivalirudin and heparin in acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by The Medicines Company. Primary endpoint: Primary composite endpoint at 30 days. Started Nov 2010; status: active, not recruiting.
02
Drugs
bivalirudinheparin
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON38053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38053.